Skip to main content
Premium Trial:

Request an Annual Quote

Biodesy Closes $10M Series B Round

NEW YORK (GenomeWeb) – Biodesy said today it has closed a $10 million Series B financing round led by existing investors 5AM Ventures, Pfizer Venture Investments, and Roche Venture Fund.

The company said that proceeds from the round would be used to expand and accelerate commercialization of its Delta System, a high-throughput platform for measuring protein conformational change.

The company also today announced that the platform is now available worldwide.

Biodesy has targeted the Delta System toward drug researchers as a tool for drug screening, hit evaluation, and mechanism of action studies. According to the company, its 20 customers include seven of the top 10 global pharmaceutical firms, and it has developed assays for roughly 100 protein constructs representing approximately 40 different proteins and more than 10 different drug target classes.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.